Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Prima BioMed initiates phase II study in ovarian cancer

Aug. 4, 2004

NY-ESO-1/ISCOMATRIX cancer vaccine shows promise in clinical study

Aug. 2, 2004

Phase II study of Theratope for metastatic breast cancer completes enrollment

July 29, 2004

Survival benefits of Canvaxin in metastatic melanoma

July 29, 2004

Combination regimens in the treatment of CTCL

July 29, 2004

Antisoma gains rights to BC1-IL12

July 28, 2004

New phase II biomarker trial for SGN-15

July 27, 2004

First phase III study of GVAX prostate cancer vaccine commences enrollment

July 21, 2004

Therapeutic benefits of recombinant PSA vaccines in advanced prostate cancer

July 13, 2004

European orphan medicinal product status for Mepat in osteosarcoma

July 12, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...